Renaissance Technologies LLC bought a new stake in PepGen Inc. (NASDAQ:PEPG – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 12,000 shares of the company’s stock, valued at approximately $192,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of PEPG. RA Capital Management L.P. increased its position in shares of PepGen by 31.5% during the 1st quarter. RA Capital Management L.P. now owns 10,689,545 shares of the company’s stock worth $157,136,000 after purchasing an additional 2,557,593 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of PepGen by 18.1% during the 1st quarter. Janus Henderson Group PLC now owns 1,166,642 shares of the company’s stock worth $17,225,000 after purchasing an additional 178,438 shares during the last quarter. Vanguard Group Inc. increased its position in shares of PepGen by 68.0% during the 1st quarter. Vanguard Group Inc. now owns 850,445 shares of the company’s stock worth $12,502,000 after purchasing an additional 344,266 shares during the last quarter. Artal Group S.A. acquired a new position in shares of PepGen during the 1st quarter worth approximately $2,940,000. Finally, Bank of New York Mellon Corp increased its position in shares of PepGen by 43.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 44,157 shares of the company’s stock worth $705,000 after purchasing an additional 13,397 shares during the last quarter. Institutional investors and hedge funds own 58.01% of the company’s stock.
PepGen Trading Up 1.8 %
PEPG stock opened at $8.81 on Friday. The firm has a market capitalization of $285.59 million, a PE ratio of -2.71 and a beta of 1.69. PepGen Inc. has a 1-year low of $3.72 and a 1-year high of $19.30. The business’s 50 day simple moving average is $9.12 and its 200 day simple moving average is $12.89.
Insider Buying and Selling at PepGen
In other PepGen news, insider Michelle L. Mellion sold 12,625 shares of the company’s stock in a transaction on Thursday, July 18th. The stock was sold at an average price of $18.20, for a total value of $229,775.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders have sold a total of 26,097 shares of company stock valued at $472,725 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
PEPG has been the topic of several recent analyst reports. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of PepGen in a research report on Wednesday, July 31st. Bank of America lowered PepGen from a “buy” rating to a “neutral” rating and set a $12.00 target price on the stock. in a report on Wednesday, July 31st. Finally, HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of PepGen in a report on Thursday, August 1st.
Get Our Latest Stock Report on PEPG
About PepGen
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Further Reading
- Five stocks we like better than PepGen
- What is the NASDAQ Stock Exchange?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Health Care Stocks Explained: Why You Might Want to Invest
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Calculate Inflation Rate
- MarketBeat Week in Review – 10/7 – 10/11
Want to see what other hedge funds are holding PEPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PepGen Inc. (NASDAQ:PEPG – Free Report).
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.